ISRG · Intuitive Surgical

321 filings

ISRG SEC Filings

Intuitive Surgical - 321 total filings

Filing record · 2016–202610-K1110-Q338-K100

Showing 1–50 of 321 filings

Intuitive Surgical 8-K Report, Executive Changes (Nov 2, 2026)

Intuitive Surgical, Inc. (ISRG) announced on November 2, 2026, a significant addition to its Board of Directors with the appointment of Aaron Martin, effective January 1, 2027. Mr. Martin brings a wealth of experience from leadership roles in healthcare technology, insurance, and digital innovation, notably as President of Insurance at Humana and previously as Vice President of Healthcare at Amazon, where he launched Amazon Clinic. His appointment is expected to enhance the Board's strategic perspective on expanding access to minimally invasive care globally, leveraging his deep understanding of payer, provider, and patient dynamics. The company has also increased its Board size from ten to eleven members to accommodate this appointment. Mr. Martin will receive standard compensation for non-employee directors, including an annual cash retainer and restricted stock units, aligning his interests with those of the company and its shareholders. This move signals a continued focus on strategic growth and operational excellence within the evolving healthcare landscape.

Nov 2, 2026 10-Q

Intuitive Surgical Quarterly Report for Q3 Ended Sep 30, 2026

Intuitive Surgical Inc. reported strong revenue growth for the third quarter and first nine months of fiscal year 2026, driven by increased da Vinci procedure volumes and system placements. Total revenue rose 22% year-over-year for the quarter and 21% for the nine-month period, reflecting robust demand for both instruments/accessories and systems. The company continues to expand its installed base for both da Vinci and Ion systems, indicating sustained market adoption. However, operating income saw a significant decrease in the quarter, largely due to a $450 million settlement charge for antitrust class action litigation. Despite this, the company maintained healthy gross profit margins and saw positive trends in recurring revenue streams. Shareholder returns were supported by substantial share repurchases, although the company's cash and investment balances decreased due to these repurchases and a business acquisition.

Oct 21, 2026 8-K

Intuitive Surgical 8-K Report, Financial Results (Oct 20, 2026)

Intuitive Surgical, Inc. (ISRG) reported its third-quarter 2026 financial results, showcasing robust top-line growth driven by increased procedure volumes and system placements. Worldwide procedures, combining da Vinci and Ion, grew approximately 15% year-over-year, with da Vinci procedures up 14% and Ion procedures seeing a significant 31% increase. This strong procedural growth translated into a 22% rise in total revenue to $3.05 billion. The company also demonstrated strong system placement growth, with 546 da Vinci systems and 56 Ion systems deployed, contributing to an expanding installed base. While revenue and procedural growth were strong, reported GAAP net income was impacted by a significant pre-tax charge of $450 million related to the settlement of antitrust class action litigation. This charge significantly affected diluted GAAP EPS, reducing it to $1.49. However, on a non-GAAP basis, which excludes this litigation charge and other items, net income grew to $1.05 billion, with non-GAAP diluted EPS reaching $3.00, indicating healthy underlying operational performance. The company also reiterated its full-year 2026 outlook, projecting continued strong da Vinci procedure growth and providing guidance for non-GAAP gross profit margin and operating expense growth.

Oct 20, 2026 8-K

Intuitive Surgical 8-K Report, Bylaw Amendment (Jul 27, 2026)

Intuitive Surgical, Inc. (ISRG) has filed an 8-K report on July 27, 2026, detailing amendments to its Amended and Restated Bylaws, effective July 23, 2026. These changes are primarily aimed at enhancing corporate governance, clarifying procedures for shareholder actions, and aligning with new SEC universal proxy rules. Key updates include stricter requirements for shareholder nominations of directors and proposals, improved disclosure obligations for shareholders seeking to nominate directors or submit proposals, and provisions related to proxy card colors and shareholder meeting logistics. These amendments are designed to streamline the shareholder engagement process and ensure compliance with evolving regulatory standards. From an investor's perspective, these bylaw amendments signify the Company's proactive approach to corporate governance and its commitment to adapting to regulatory changes. The refined disclosure requirements for shareholder proposals and nominations provide greater transparency and may help the board in evaluating such submissions. The change in the voting standard for corporate actions to a majority of votes cast is a notable shift that could impact the outcome of future non-election-related shareholder votes. Investors should review the full text of the Amended Bylaws to understand the complete scope of these changes and their potential implications on future shareholder rights and corporate decision-making processes.

Jul 27, 2026 10-Q

Intuitive Surgical Quarterly Report for Q2 Ended Jun 30, 2026

Intuitive Surgical Inc. reported strong financial performance for the six months ended June 30, 2026, with total revenue increasing by 21% year-over-year to $5.66 billion. This growth was driven by robust increases in both product revenue (21%) and service revenue (20%). The company saw significant expansion in its da Vinci surgical system placements, up 18% year-over-year in the second quarter, alongside a 36% surge in Ion procedures, indicating strong adoption of its robotic-assisted surgical and diagnostic platforms. Profitability also improved, with operating income rising 31% in the second quarter, reflecting healthy gross profit margins. The company continued to execute on its capital allocation strategy, repurchasing approximately $1.51 billion of its common stock in the first six months of the year, while maintaining a strong cash and investment balance of $8.63 billion.

Jul 21, 2026 8-K

Intuitive Surgical 8-K Report, Financial Results (Jul 16, 2026)

Intuitive Surgical (ISRG) reported strong second-quarter 2026 results, with revenue of $2.89 billion, up 19% year over year from $2.44 billion. Worldwide procedures (da Vinci and Ion combined) grew approximately 16%, with da Vinci procedures up about 15% and Ion procedures up about 36%. Instruments and accessories revenue rose 18% to $1.73 billion, and systems revenue increased to $685 million from $575 million, supported by 468 da Vinci placements (including 246 da Vinci 5 systems). GAAP operating margin was about 33.6% (income from operations of $972 million), and non-GAAP operating income was $1.22 billion. GAAP diluted EPS was $2.29 and non-GAAP diluted EPS was $2.80, both including a one-time $0.08 benefit from IEEPA tariff refunds. Gross margin improved sequentially, with GAAP gross margin of 67.8% and non-GAAP gross margin of 70.0%, the latter helped by the tariff refund benefit. Management reiterated that 2026 da Vinci procedure growth should be closer to the midpoint of its 13.5% to 15.5% range, while non-GAAP gross margin is guided to 68.0% to 69.0% and non-GAAP operating expense growth to 11% to 13%. The guidance includes an estimated 1.0% of revenue tariff impact, and management warned that any additional tariffs could have a material effect. Cash and investments ended the quarter at $8.63 billion, and the company repurchased $0.38 billion of stock. For investors, the key points are sustained double-digit growth in procedures and systems placements, continued expansion of the installed base to 11,710 da Vinci systems, and the Italy, Spain, and Portugal distributor-to-direct transition, which added goodwill. Some of the quarter's margin and EPS strength reflects one-time tariff refunds, and the company's trajectory depends on tariff developments and continued procedure growth. Note that this 8-K furnishes the earnings release under Item 2.02 and does not describe any new material event beyond the results and outlook.

Jul 16, 2026 8-K

Intuitive Surgical 8-K Report, Executive Changes (May 28, 2026)

Intuitive Surgical (ISRG) filed an 8-K on May 28, 2026 announcing a senior leadership change in its commercial organization. Effective July 1, 2026, Taylor Patton, currently Global Senior Vice President of the Endoluminal business (Ion platform), will become Chief Commercial and Marketing Officer, succeeding Henry Charlton. Charlton, who has been with the company since 2003, will move to the newly defined role of Senior Vice President of Global Business Operations. From an investor standpoint, this is a planned internal succession rather than a signal of operational distress. Patton has nearly two decades of tenure at Intuitive and a record of launching new platforms and building commercial organizations, most notably the worldwide launch and growth of the Ion endoluminal system. Charlton is remaining with the company in a senior operating role and is expected to work closely with Patton during the handoff, which points to a managed transition. The filing does not disclose any change in compensation, employment agreements, or financial guidance. The main items to monitor are whether the handover affects commercial execution across the da Vinci and Ion franchises, and whether Patton's focus on reducing total cost to treat and expanding customer support translates into placements, procedure volume, and pricing discipline in coming quarters. The filing itself contains no quantitative financial results.

May 28, 2026 8-K

Intuitive Surgical 8-K Report, Executive Changes (May 4, 2026)

Intuitive Surgical, Inc. (ISRG) filed an 8-K on May 4, 2026, reporting on key outcomes from its Annual Meeting of Stockholders held on April 30, 2026. The primary focus for investors is the approval of an amended and restated 2010 Incentive Award Plan, which increases the share reserve by 5 million shares, extends the plan's term to January 2036, and clarifies change-in-control provisions. This demonstrates a continued commitment to employee and executive compensation through equity, a common practice for growth-oriented companies. Furthermore, the filing details the successful election of all ten director nominees, indicating shareholder confidence in the current board's leadership. Stockholders also provided advisory approval for executive compensation and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. In a significant move for capital allocation, the company announced on April 30, 2026, that its Board of Directors increased the authorized amount available under its common stock repurchase program to an aggregate of $5.0 billion, signaling a strong belief in the company's valuation and a commitment to returning capital to shareholders.

May 4, 2026 10-Q

Intuitive Surgical Quarterly Report for Q1 Ended Mar 31, 2026

Intuitive Surgical, Inc. (ISRG) reported strong financial results for the first quarter ended March 31, 2026, demonstrating robust top-line growth and improving profitability. Total revenue increased by a significant 23% year-over-year to $2.77 billion, driven by a 24% increase in systems revenue and a 23% increase in instruments and accessories revenue. This growth was supported by a substantial increase in da Vinci procedures, up 16%, and Ion procedures, up 39%. The company also saw a healthy increase in da Vinci system placements, up 17%, and a growing installed base for both da Vinci and Ion systems. Profitability improved, with gross profit margin rising to 66.1% and operating income growing by 48% to $855 million. Net income attributable to Intuitive Surgical, Inc. also saw a healthy increase. The company's balance sheet remains strong, although cash and investments decreased due to significant share repurchases and a strategic business acquisition. The company continues to invest in research and development, reflecting its commitment to innovation and future growth, while also managing potential macroeconomic and geopolitical headwinds.

Apr 22, 2026 8-K

Intuitive Surgical 8-K Report, Financial Results (Apr 21, 2026)

Intuitive Surgical (ISRG) reported strong first-quarter 2026 results, with revenue of $2.77 billion, up 23% year over year, driven by about 17% growth in worldwide procedures (da Vinci about 16%, Ion about 39%). GAAP income from operations rose to $855 million from $578 million, and GAAP diluted EPS was $2.28 versus $1.92. Non-GAAP diluted EPS was $2.50 versus $1.81. Systems revenue grew to $651 million on 431 da Vinci placements (232 da Vinci 5), up from 367 placements a year earlier, and the installed base reached 11,395 da Vinci systems, up 12%. The quarter also showed some balance sheet and capital allocation movement. Cash, cash equivalents, and investments fell by $1.05 billion to $7.98 billion, reflecting $1.1 billion of share repurchases (2.3 million shares) and an acquisition, which the filing links to the purchase of da Vinci and Ion distribution businesses in Italy, Spain, and Portugal. Goodwill rose from $370 million to $613 million, consistent with that acquisition. Sequentially, revenue declined from $2.87 billion in Q4 2025, which included a $70 million contribution to the Intuitive Foundation, and GAAP gross margin improved to 66.1%. Management reiterated 2026 guidance for worldwide da Vinci procedure growth of 13.5% to 15.5%, non-GAAP gross margin of 67.5% to 68.5% (including about a 1.0% tariff impact), and non-GAAP operating expense growth of 11% to 14%. The company flagged that additional tariffs beyond current expectations could materially affect results. Investors should note that non-GAAP EPS benefits from excluding share-based compensation (about $210 million per quarter) and excess tax benefits (about $73 million this quarter), which contributed meaningfully to the gap between GAAP and non-GAAP earnings.

Apr 21, 2026 8-K

Intuitive Surgical 8-K Report, Corporate Update (Mar 2, 2026)

On March 2, 2026, Intuitive Surgical (ISRG) filed an 8-K disclosing the completion, on March 1, 2026, of its acquisition of the da Vinci and Ion distribution business operated by ab medica, Abex, Excelencia Robótica, and their affiliates. The transaction converts these businesses from third-party distribution into wholly owned, direct operations across Italy, Spain, Portugal, Malta, San Marino, and associated territories. The business is now integrated into Intuitive's European commercial and marketing organization, led by SVP and GM Dirk Barten, and brings roughly 250 employees onto Intuitive's payroll. For investors, the strategic rationale is a shift toward a more direct, agile customer relationship in Southern Europe, a region where Intuitive has operated for more than two decades. The combined installed base exceeds 470 da Vinci systems in Italy, Spain and Portugal as of December 31, 2025, and the Ion endoluminal system was recently launched in Italy and Spain. Owning distribution rather than relying on third parties should give Intuitive more control over pricing, service, and placements, and it captures revenue and margin that previously flowed to distributors, though the filing does not disclose purchase price, financial terms, or the acquired business's revenue. The 8-K is an event disclosure rather than a financial report. It contains no quantitative financial results, guidance changes, or purchase accounting details, so investors should look to upcoming periodic filings and earnings commentary for the financial impact, integration costs, and effect on reported European revenue and operating margins.

Mar 2, 2026 10-K

Intuitive Surgical Annual Report, Year Ended Dec 31, 2025

Intuitive Surgical Inc. (ISRG) reported robust growth in its 2025 fiscal year, with total revenue increasing by 21% to $10.1 billion. This growth was driven by a significant increase in da Vinci procedures (up 18%) and Ion procedures (up 51%), indicating strong adoption of the company's minimally invasive robotic surgical systems and diagnostic platforms. The company saw substantial growth in both systems revenue (+26%) and instruments and accessories revenue (+19%), reflecting increased unit placements for its da Vinci surgical systems, particularly the new da Vinci 5 model. The installed base of da Vinci systems grew by 12% to over 11,100 units, while the Ion system installed base increased by 24%. Despite strong revenue growth, the gross profit margin for products decreased slightly to 66.0% from 67.5% in the prior year, attributed to factors including new tariffs, higher costs associated with the da Vinci 5, and increased depreciation, though partially offset by lower excess inventory charges. Looking ahead, ISRG continues to invest heavily in research and development to drive innovation, while also navigating macroeconomic challenges such as tariffs, inflation, and supply chain constraints. The company's financial position remains strong, with over $9 billion in cash, cash equivalents, and investments, providing ample resources to fund future growth and strategic initiatives.

Feb 3, 2026 8-K

Intuitive Surgical 8-K Report, Financial Results (Jan 22, 2026)

Intuitive Surgical (ISRG) reported strong fourth-quarter 2025 results, with total revenue of $2.87 billion, up 19% year over year, and GAAP net income attributable to Intuitive of $795 million, or $2.21 per diluted share (non-GAAP EPS of $2.53, up from $2.21). Growth was broad-based: worldwide procedures (da Vinci plus Ion) rose about 18%, da Vinci placements reached 532 units (303 da Vinci 5 systems, versus 174 a year earlier), and the installed base grew 12% to 11,106 da Vinci systems. Ion procedures grew about 44% and the Ion installed base reached 995 systems. Instruments and accessories revenue rose 17% to $1.66 billion, supporting the recurring-revenue model. Full-year 2025 revenue was $10.06 billion, up roughly 20%, and GAAP net income attributable to Intuitive was $2.86 billion. The outlook calls for 2026 worldwide da Vinci procedure growth of 13% to 15%, a slowdown from 18% in 2025. Non-GAAP gross margin is guided to 67% to 68%, including an estimated 1.2% of revenue tariff headwind, and non-GAAP operating expense growth is guided to 11% to 15%. Management cautioned that additional or modified tariffs could have a material effect on 2026 margins. Investors will likely focus on whether procedure growth can hold in the mid-teens and how tariffs and rising operating expenses affect margin expansion. Quality-of-earnings considerations also matter. GAAP results include large share-based compensation ($207 million in Q4), and non-GAAP figures exclude it, along with excess tax benefits that contributed $0.12 per diluted share in the quarter. The quarter also included a $70 million contribution to the Intuitive Foundation, which reduced GAAP EPS by about $0.15. Cash, cash equivalents, and investments ended the year at $9.03 billion.

Jan 22, 2026 8-K

Intuitive Surgical 8-K Report, Financial Results (Jan 14, 2026)

Intuitive Surgical (ISRG) preliminarily reported strong fourth-quarter and full-year 2025 results ahead of its J.P. Morgan Healthcare Conference presentation. Q4 2025 revenue was approximately $2.87 billion, up 19% from $2.41 billion, and full-year 2025 revenue was approximately $10.06 billion, up 21% from $8.35 billion. Growth was broad-based: instruments and accessories (I&A) revenue rose 17% in Q4 to $1.66 billion and 19% for the year to $6.02 billion, systems revenue rose 20% in Q4 to $786 million and 26% for the year to $2.47 billion, and service revenue rose 21% in Q4 to $422 million and 20% for the year to $1.57 billion. Recurring revenue was 81% of Q4 total revenue. Worldwide da Vinci procedures grew about 17% in Q4 and 18% for 2025 to roughly 3.15 million, led by 18% U.S. general surgery growth and 23% growth outside the U.S. The installed base reached 11,106 systems, up 12%, and the average selling price rose 7% for the year to $1.60 million. Placement mix shifted toward da Vinci 5, which drove most of the placement growth. Q4 placements totaled 532 systems (up 8%), including 303 da Vinci 5 units, and full-year placements reached 1,721 (up 13%), including 870 da Vinci 5 units versus 362 in 2024. Ion placements declined, with 42 units in Q4 (down 39%) and 195 for the year (down 28%), even though Ion procedures grew about 44% in Q4 and 51% for the year. Q4 operating expenses included a $70 million contribution to the Intuitive Foundation, up from $45 million a year earlier. Management guided to worldwide da Vinci procedure growth of 13% to 15% in 2026. All figures are unaudited and preliminary. The 2025 Form 10-K has not yet been filed, and the numbers remain subject to final closing procedures and the independent audit. Management will discuss the results in more detail on the January 22, 2026 earnings call.

Jan 14, 2026 8-K

Intuitive Surgical 8-K Report, Executive Changes (Dec 18, 2025)

Intuitive Surgical, Inc. (ISRG) has announced a leadership transition effective January 1, 2026. Brian E. Miller, Ph.D., will be stepping down as Chief Digital Officer. While this role change might initially suggest a shift in focus, Dr. Miller will remain with the company in a newly created position: Head of Digital and AI Strategy. This move indicates a continued commitment to advancing the company's digital and artificial intelligence initiatives, albeit with a restructured reporting line.

Dec 18, 2025 10-Q

Intuitive Surgical Quarterly Report for Q3 Ended Sep 30, 2025

Intuitive Surgical Inc. (ISRG) reported strong revenue growth for the third quarter and first nine months of fiscal year 2025, with total revenue increasing by 23% and 21%, respectively, year-over-year. This growth was driven by robust performance across all segments, including a significant increase in instruments and accessories revenue (20% and 19%) and systems revenue (33% and 29%). The company also saw substantial growth in da Vinci procedures (19% and 18% for the quarter and nine months, respectively) and Ion procedures (52% and 54%). The company continues to expand its installed base, with da Vinci systems increasing by 13% year-over-year and Ion systems by 30%. Profitability also saw a significant boost, with operating income up 32% year-over-year for the quarter. Despite the strong top-line and bottom-line performance, investors should note a slight decline in gross profit margin as a percentage of revenue for both product and service segments, primarily attributed to the impact of tariffs and increased costs related to the phased launch of the new da Vinci 5 system. The company also repurchased a significant amount of its common stock, totaling $1.92 billion in the third quarter. Management remains optimistic about future growth, driven by expanding procedure adoption, new product introductions, and international market penetration, though they acknowledge ongoing macroeconomic and geopolitical risks.

Oct 22, 2025 8-K

Intuitive Surgical 8-K Report, Financial Results (Oct 21, 2025)

Intuitive Surgical (ISRG) reported third quarter 2025 results on October 21, 2025, with broad-based strength across its core businesses. Total revenue rose 23% year over year to $2.51 billion, driven by roughly 19% growth in da Vinci procedures and about 52% growth in Ion procedures. GAAP net income attributable to Intuitive was $704 million ($1.95 per diluted share), up from $565 million ($1.56) a year earlier, while non-GAAP EPS was $2.40 versus $1.84. The non-GAAP figure includes $0.12 per share of one-time tax benefits from U.S. tax reform and the release of unrecognized tax benefits, so the underlying growth rate is somewhat lower than the headline suggests. Installed base growth remained healthy, with 427 da Vinci placements (240 of them da Vinci 5) and the da Vinci installed base reaching 10,763 systems, up 13%. The main caution for investors is margin. Management now expects 2025 non-GAAP gross margin of 67% to 67.5%, down from 69.1% in 2024, with tariffs estimated to cost about 0.7% of revenue. Management also raised its expected non-GAAP operating expense growth to 11% to 13%, and it guided worldwide da Vinci procedure growth of 17% to 17.5% for the full year. Cash, equivalents and investments fell by $1.10 billion in the quarter to $8.43 billion, largely because of $1.92 billion in share repurchases and capital expenditures. The company is returning substantial capital, but it is also absorbing rising tariff and manufacturing costs, and the new tariff guidance carries additional risk if policy changes. This 8-K furnishes the earnings press release under Item 2.02, and the information is not deemed filed for Section 18 purposes. The filing itself contains no new operating events or legal disclosures beyond the press release. Investors should focus on the margin trajectory and the sustainability of procedure growth, since both will determine whether earnings growth keeps pace with revenue growth.

Oct 21, 2025 10-Q

Intuitive Surgical Quarterly Report for Q2 Ended Jun 30, 2025

Intuitive Surgical, Inc. (ISRG) reported strong financial performance for the quarter and first half of 2025, demonstrating robust revenue growth across its key segments. Total revenue increased by 21% year-over-year to $2.44 billion for the three months ended June 30, 2025. This growth was driven by a significant uptick in da Vinci procedure volume (up 17%), higher systems revenue (up 28%), and increased instruments and accessories revenue (up 18%), signaling continued adoption and utilization of their robotic-assisted surgical systems. The company also saw a substantial increase in Ion endoluminal system procedures, up 52% year-over-year, highlighting the growing adoption of their diagnostic platform. Despite increased costs related to the launch of the da Vinci 5 system, tariffs, and expanded manufacturing capacity, gross profit margin remained solid at 66.3%. Operating income saw a healthy increase of 31% to $743 million. The company ended the period with a strong cash position of $3.4 billion and significant investments, underscoring its financial health and capacity for future growth and strategic initiatives.

Jul 23, 2025 8-K

Intuitive Surgical 8-K Report, Financial Results (Jul 22, 2025)

Intuitive Surgical (ISRG) reported Q2 2025 results that were strong on nearly every headline metric. Revenue rose 21% year over year to $2.44 billion, with worldwide da Vinci procedure growth of approximately 17% and Ion procedure volume up roughly 52%. The company placed 395 da Vinci systems (versus 341 a year earlier), including 180 da Vinci 5 systems (versus 70), and the installed base reached 10,488 systems, up 14%. GAAP net income attributable to Intuitive was $658 million ($1.81 per diluted share), and non-GAAP EPS was $2.19 versus $1.78. GAAP income from operations rose to $743 million from $567 million, and the company ended the quarter with $9.53 billion in cash and investments. The key watch item is margin. Management narrowed its 2025 non-GAAP gross margin guidance to 66%-67%, down from 69.1% in 2024, citing an estimated tariff impact of about 1.0% of revenue, and warned that additional or modified tariffs could have a material effect. Management also guided to worldwide da Vinci procedure growth of 15.5%-17% and non-GAAP operating expense growth of 10%-14%. Investors should note that Q2 GAAP net income was flattered by a large excess tax benefit from share-based compensation ($33 million, or $0.09 per share), and that Q1 GAAP net income benefited from an unusually large $145 million excess tax benefit. Quarterly comparisons are therefore noisier than the top-line trend suggests. Overall, the quarter shows robust demand, accelerating da Vinci 5 adoption, and continued expansion of the installed base, with the principal risks centered on tariff-driven gross margin pressure and macroeconomic or regulatory developments. The company also announced EU MDR certification for da Vinci 5 (excluding force feedback) and Japanese clearance for da Vinci 5 across most specialties. This 8-K furnishes the earnings press release under Item 2.02 and is not deemed filed under Section 18 of the Exchange Act.

Jul 22, 2025 8-K

Intuitive Surgical 8-K Report, Executive Changes (May 15, 2025)

Intuitive Surgical (ISRG) announced on May 15, 2025 (via Form 8-K) a planned CEO transition effective July 1, 2025. Board-appointed President David J. Rosa, a 29-year Intuitive veteran who has served as President since May 2023 and as a director since July 2024, will succeed Gary S. Guthart, Ph.D., as Chief Executive Officer. Guthart, who has led the company for roughly 15 years, will become Executive Chair of the Board and remain an employee in a senior advisory role. Craig H. Barratt, Ph.D., the current Board Chair, will become Lead Independent Director. The changes reflect the board's succession planning rather than any disclosed performance concern, and the filing contains no reported financial results or guidance changes. For investors, the key economic terms relate to compensation. Rosa's base salary rises from $825,000 to $925,000, his target bonus increases from 125% to 150% of base salary, and he receives new equity grants of $4 million in RSUs (vesting 25% annually over four years) and $4 million in PSUs (vesting 0-125% of target on February 26, 2028 based on performance). Guthart's base salary falls from $1,050,000 to $700,000 and he will no longer be eligible for the Corporate Incentive Program bonus going forward, though he will receive a prorated FY2025 bonus for his CEO service. The Company also disclosed no related-person transactions requiring reporting under Item 404(a). From a strategic standpoint, the transition is orderly and planned: the outgoing CEO remains involved as Executive Chair, and the incoming CEO has deep, long-standing operational and strategic experience, including founding the clinical engineering and endoluminal groups that led to the da Vinci SP and Ion systems. Investors will likely focus on whether continuity of strategy and product execution holds through the handover and on how the new leadership approaches growth, global expansion, and the Quintuple Aim priorities.

May 15, 2025 8-K

Intuitive Surgical 8-K Report, Executive Changes (May 5, 2025)

Intuitive Surgical Inc. (ISRG) filed an 8-K report detailing outcomes from their Annual Meeting of Stockholders held on May 1, 2025, and an increase in their stock repurchase program. Key among the meeting's outcomes was the stockholder approval of the amendment and restatement of the Amended and Restated 2010 Incentive Award Plan. This amendment increases the number of shares reserved for issuance by 5 million, extends the plan's term to January 30, 2035, and clarifies treatment of awards in change-in-control scenarios. Additionally, all eleven director nominees were elected to the Board, and advisory approval was given for executive compensation. Further enhancing shareholder value initiatives, the Board of Directors approved an increase to the common stock repurchase program by $4.0 billion, encompassing previously authorized but unused amounts. This signifies management's confidence in the company's financial health and commitment to returning capital to shareholders. While most proposals passed with strong support, two shareholder proposals concerning executive compensation and golden parachutes were rejected by a significant margin.

May 5, 2025 10-Q

Intuitive Surgical Quarterly Report for Q1 Ended Mar 31, 2025

Intuitive Surgical Inc. (ISRG) reported strong financial results for the first quarter of 2025, demonstrating robust top-line growth and continued expansion in its core robotic surgery business. Total revenue increased by a significant 19% year-over-year to $2.25 billion, driven by strong performance across all revenue segments, particularly in instruments and accessories, systems, and services. The company saw a substantial increase in da Vinci procedure volume, up 17%, alongside a notable 58% surge in Ion endoluminal procedures, indicating growing adoption of its minimally invasive solutions. Key financial metrics highlight the company's operational efficiency and continued investment in innovation. Gross profit margin remained healthy at 64.7%, with operating income growing 23%. The company also reported a healthy cash position, ending the quarter with $9.10 billion in cash, cash equivalents, and investments, providing ample liquidity for future growth initiatives, ongoing R&D, and potential strategic acquisitions. The increase in systems revenue and strong da Vinci 5 system placements signal positive market reception for newer generation products.

Apr 23, 2025 8-K

Intuitive Surgical 8-K Report, Financial Results (Apr 22, 2025)

Intuitive Surgical (ISRG) reported first quarter 2025 results on April 22, 2025, showing strong top-line and procedure growth. Revenue rose 19% year over year to $2.25 billion, driven by roughly 17% growth in da Vinci procedure volume and about 58% growth in Ion procedure volume. The company placed 367 da Vinci systems (versus 313 a year earlier), including 147 da Vinci 5 systems (versus 8), and the installed base grew 15% to 10,189 systems. GAAP net income attributable to Intuitive was $698 million, or $1.92 per diluted share, versus $1.51 a year earlier. Non-GAAP EPS was $1.81, up from $1.50, though the GAAP figure was boosted by $145 million of excess tax benefits from share-based compensation ($0.40 per share), which management excludes from non-GAAP results. The main caution in the filing is the margin outlook. Management lowered its expected 2025 non-GAAP gross margin to 65% to 66.5%, versus 69.1% in 2024, and attributed about 1.7 percentage points of that pressure to tariffs. The company warned that additional tariffs could have a material adverse effect, particularly depending on China system sales and the share of components sourced or manufactured outside the U.S. Q1 non-GAAP gross margin was about 66.4% (1,496.6 / 2,253.4), and non-GAAP operating expense growth is guided at 10% to 14%. Procedure growth guidance is 15% to 17%, down slightly from 17% in 2024. Balance sheet strength continued, with cash, cash equivalents, and investments reaching $9.10 billion, up $269 million in the quarter. Operating cash generation was partly offset by taxes paid on net share settlement of equity awards and capital expenditures. Management's commentary emphasized customer adoption of da Vinci 5 and the company's focus on patient outcomes and lower total cost to treat. The filing itself is an earnings release furnished under Item 2.02 and is not deemed filed under the Exchange Act.

Apr 22, 2025 10-K

Intuitive Surgical Annual Report, Year Ended Dec 31, 2024

Intuitive Surgical, Inc. (ISRG) filed its annual report for the period ending December 30, 2024, highlighting robust revenue growth and continued expansion of its da Vinci surgical system installed base. Total revenue increased by 17% to $8.4 billion, driven by a strong performance in instruments and accessories revenue (up 19%) and systems revenue (up 17%). The company also saw significant growth in its Ion endoluminal system procedures (up 78%). The da Vinci system installed base grew 15% to 9,902 units globally, with 1,526 new systems placed during the year. This growth reflects increasing adoption across key surgical specialties, particularly in general surgery, gynecology, and urology, both domestically and internationally. The company is also investing in new product development, including the next-generation da Vinci 5 system and the E-200 generator, and expanding its manufacturing capabilities. Despite strong operational performance, the company faces ongoing risks including intense competition, potential disruptions to its supply chain, regulatory complexities, and macroeconomic headwinds such as inflation and interest rate volatility. The company's significant international operations also expose it to currency fluctuations and varied regulatory environments. Management remains focused on innovation, expanding access to minimally invasive care, and optimizing its business strategy to navigate these challenges and capitalize on future growth opportunities.

Jan 31, 2025 8-K

Intuitive Surgical 8-K Report, Financial Results (Jan 23, 2025)

Intuitive Surgical (ISRG) reported strong fourth-quarter 2024 results, with total revenue of $2.41 billion, up 25% year over year, driven by roughly 18% growth in da Vinci procedure volume and roughly 70% growth in Ion procedure volume. GAAP net income attributable to Intuitive was $686 million, or $1.88 per diluted share, versus $1.69 a year earlier, and non-GAAP EPS was $2.21 versus $1.60. The company placed 493 da Vinci systems (including 174 da Vinci 5 units), grew its installed base 15% to 9,902 systems, and ended the year with $8.83 billion in cash and investments. Full-year 2024 GAAP diluted EPS was $6.42 and non-GAAP EPS was $7.34. For 2025, management guided to worldwide da Vinci procedure growth of 13% to 16% (versus 17% in 2024), a non-GAAP gross margin of 67% to 68% (versus 69.1% in 2024), and non-GAAP operating expense growth of 10% to 15%. Management explicitly stated the gross margin outlook excludes potential new tariffs, which could be material, a key risk given that Intuitive manufactures a significant majority of its instruments in Mexico. Investors should weigh the strong growth momentum against this margin pressure and the tariff uncertainty. Separately, on January 21, 2025, Intuitive agreed to acquire the da Vinci and Ion distribution businesses in Italy, Spain, Portugal, Malta, San Marino, and associated territories from its current distributors ab medica, Abex, and Excelencia Robotica. The upfront cash payment is approximately €290 million, plus up to €31 million in commercial milestone payments, subject to closing adjustments. The transaction is expected to close in the first half of 2026, bringing these markets under direct Intuitive ownership.

Jan 23, 2025 8-K

Intuitive Surgical 8-K Report, Financial Results (Jan 15, 2025)

Intuitive Surgical reported preliminary, unaudited fourth quarter and full year 2024 results ahead of its J.P. Morgan Healthcare Conference presentation. Fourth quarter revenue was approximately $2.41 billion, up 25% from $1.93 billion, and full year revenue was approximately $8.35 billion, up 17% from $7.12 billion. Growth was broad-based across segments: instruments and accessories (I&A) rose 23% in the quarter, systems revenue rose 36% (helped by a lower mix of leased systems and higher average selling prices), and services rose 14%. Worldwide da Vinci procedures grew approximately 18% in the quarter and 17% for the year to about 2.68 million, driven by U.S. general surgery (+19% for the year) and outside-the-U.S. procedures (+23%, led by cancer procedures). Management guided to 13% to 16% worldwide da Vinci procedure growth in 2025, though it did not provide revenue or earnings guidance in this filing. System placements also accelerated in the fourth quarter, with 493 da Vinci systems placed (+19%), including 174 da Vinci 5 systems. For the full year, 1,526 systems were placed (+11%), including 362 da Vinci 5 systems. Usage-based operating leases continued to grow, reaching 467 systems for the year (+32%). Several metrics were softer, however: Asia placements fell 13% in the quarter, trade-in placements fell 38% for the year, and Xi-generation placements declined as customers shifted toward da Vinci 5. The company also reported a $45 million contribution to the Intuitive Foundation in Q4 2024, versus $40 million a year earlier. All figures are preliminary and subject to final closing procedures and the annual audit, so they may change. The company has not yet filed its 2024 Form 10-K. Investors should look to the January 23, 2025 earnings call for detailed commentary on margins, expenses, and the 2025 outlook.

Jan 15, 2025 8-K

Intuitive Surgical 8-K Report, Executive Changes (Jan 6, 2025)

Intuitive Surgical, Inc. (ISRG) has filed an 8-K report detailing significant executive promotions effective January 1, 2025. Jamie E. Samath has been elevated to Executive Vice President, Chief Financial Officer, and Head of Business Technology. Concurrently, Henry L. Charlton has been promoted to Executive Vice President, Chief Commercial and Marketing Officer. These appointments signify a recognition of their contributions and likely reflect a strategic alignment within the company's leadership structure as it continues to navigate the evolving landscape of robotic-assisted surgery.

Jan 6, 2025 10-Q

Intuitive Surgical Quarterly Report for Q3 Ended Sep 30, 2024

Intuitive Surgical Inc. (ISRG) reported strong third-quarter results for the period ending September 29, 2024, demonstrating robust top-line growth and improving profitability. Total revenue surged 17% year-over-year to $2.04 billion, fueled by significant increases in both instruments and accessories revenue (+18%) and systems revenue (+17%). This growth was primarily driven by a 17% increase in total da Vinci procedures and the successful launch and placement of 110 new da Vinci 5 systems during the quarter. The company also reported a substantial increase in operating income, up 24% to $577 million, reflecting improved gross margins to 67.4% and effective management of operating expenses. This strong financial performance, coupled with a growing installed base of da Vinci and Ion systems, positions Intuitive Surgical favorably. The company maintains a healthy balance sheet with $8.31 billion in cash, cash equivalents, and investments, providing ample resources for continued investment in innovation and global expansion.

Oct 18, 2024 8-K

Intuitive Surgical 8-K Report, Financial Results (Oct 17, 2024)

Intuitive Surgical reported strong third-quarter 2024 results, with revenue of $2.04 billion, up 17% year over year, driven by about 18% growth in da Vinci procedure volume and a 15% larger installed base of 9,539 systems. GAAP net income attributable to Intuitive was $565 million, or $1.56 per diluted share, compared with $1.16 a year earlier. Non-GAAP EPS was $1.84, up from $1.46. Gross margin was about 67.4% (GAAP) versus 66.9% a year earlier, and GAAP operating margin expanded to about 28.3% from 26.7%, reflecting operating leverage as revenue grew faster than operating expenses. The quarter's mix shows broad-based demand. Instruments and accessories revenue rose 18% to $1.26 billion, supported by approximately 73% growth in Ion procedure volume. Systems revenue increased to $445 million from $379 million on 379 placements, of which 110 were da Vinci 5 systems, and 220 placements were under operating leases, 141 of them usage-based. Services revenue grew to $329 million from $293 million. Cash, cash equivalents, and investments reached $8.31 billion, up $628 million in the quarter, largely from operating cash flow. The company also disclosed South Korean clearance for the da Vinci 5 in October 2024. The filing contains no formal forward guidance, and it flags macroeconomic, supply chain, regulatory, and hospital capital spending risks. Investors should note the gap between GAAP and non-GAAP results. Share-based compensation of $173 million and excess tax benefits of $0.12 per share are excluded from non-GAAP figures. Excess tax benefits boosted GAAP EPS in the quarter. Management has also noted that the long-term incentive plan expense tied to the Intuitive-Fosun joint venture can be volatile, so the GAAP figures warrant attention alongside the non-GAAP measures.

Oct 17, 2024 8-K

Intuitive Surgical 8-K Report, Executive Changes (Jul 25, 2024)

Intuitive Surgical (ISRG) filed an 8-K on July 25, 2024 to disclose that David J. Rosa, the company's President, has been appointed to its Board of Directors effective July 24, 2024. The Board simultaneously increased its authorized size from eleven to twelve members, creating a newly established seat that Rosa fills. The filing reports no related-party transactions involving Rosa requiring disclosure under Item 404(a) of Regulation S-K. The appointment places two Intuitive executives on the Board: Rosa and CEO Gary S. Guthart, PhD. According to the press release furnished as Exhibit 99.1, Rosa oversees the company's core business operations, including the business unit, quality, regulatory, manufacturing, and commercial functions, while Guthart focuses on enterprise strategy and corporate functions. The company characterizes this division as adding balance between strategy and operations at the Board level. Rosa has served as President since May 2023, has nearly 27 years of tenure at Intuitive, and chairs the board of Intuitive-Fosun, the joint venture with Fosun Pharma in Shanghai. For investors, this is primarily a governance update rather than a material financial event; the filing contains no financial results, guidance, or changes to compensation arrangements. The more notable signal is the elevation of operating leadership into the Board, which may be viewed as a sign of management succession planning and deeper board-level oversight of day-to-day operations.

Jul 25, 2024 10-Q

Intuitive Surgical Quarterly Report for Q2 Ended Jun 30, 2024

Intuitive Surgical Inc. (ISRG) reported strong revenue growth in the second quarter of 2024, with total revenue increasing by 14% year-over-year to $2.01 billion. This growth was driven by robust performance in instruments and accessories, systems, and services, fueled by a 17% increase in da Vinci procedures and an impressive 82% surge in Ion procedures. The company also saw a healthy 14% increase in da Vinci system placements and a significant 56% expansion in its Ion system installed base. Profitability metrics improved, with gross profit margin increasing to 68.3% and operating income growing by 22%. The company maintains a strong balance sheet with $7.68 billion in cash, cash equivalents, and investments, indicating solid financial health and capacity for continued investment in growth and innovation.

Jul 19, 2024 8-K

Intuitive Surgical 8-K Report, Financial Results (Jul 18, 2024)

Intuitive Surgical reported strong second-quarter 2024 results, with revenue of $2.01 billion, up 14% from $1.76 billion a year earlier. Worldwide da Vinci procedures grew about 17%, and Ion procedures grew about 82%. Instruments and accessories revenue rose 16% to $1.24 billion, the main driver of the top-line growth. Systems revenue increased to $448 million from $393 million on 341 da Vinci placements, including 70 da Vinci 5 units. The installed base reached 9,203 systems, up 14% year over year. Gross margin improved to about 68.3% on a GAAP basis from about 66.7% a year earlier, and GAAP income from operations rose 22% to $567 million. Management described the business as healthy and highlighted feedback on da Vinci 5 and continued adoption of SP and Ion. Profitability was also strong. GAAP net income attributable to Intuitive was $527 million, or $1.46 per diluted share, compared with $1.18 a year earlier. Non-GAAP net income was $641 million, or $1.78 per diluted share, versus $1.42. The GAAP and non-GAAP gap is driven mainly by share-based compensation and excess tax benefits of $36 million, or $0.10 per share. A $7.2 million litigation charge was excluded from non-GAAP results. Cash, cash equivalents, and investments ended the quarter at $7.68 billion, up $360 million in the quarter, supported by operating cash flow and partially offset by capital expenditures. The 8-K is a routine earnings disclosure furnished under Item 2.02, so it is not deemed filed for Section 18 purposes. It contains no forward guidance; the full outlook would be found on the earnings call and in the press release's forward-looking statements. Investors should note that a higher share of placements was under operating leases (175 of 341, including 92 usage-based), which shifts revenue recognition toward recurring usage and makes system revenue less immediate.

Jul 18, 2024 8-K

Intuitive Surgical 8-K Report, Executive Changes (Apr 30, 2024)

Intuitive Surgical, Inc. filed an 8-K report on April 29, 2024, detailing key events from its Annual Stockholders' Meeting held on April 24, 2024. The primary focus for investors is the outcome of the shareholder votes, which saw all incumbent directors re-elected and approval of executive compensation on an advisory basis. Significant governance changes include the appointment of Lewis Chew as the new Chair of the Audit Committee and Jami Dover Nachtsheim as the new Chair of the Governance and Nominating Committee. Investors will also note the approval of the amendment and restatement of both the 2010 Incentive Award Plan and the 2000 Employee Stock Purchase Plan, indicating continued support for the company's equity incentive structures. The ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024 reinforces auditor confidence. Importantly, a shareholder proposal requesting a racial and gender pay gap report was narrowly rejected, highlighting ongoing discussions around corporate social responsibility metrics.

Apr 30, 2024 10-Q

Intuitive Surgical Quarterly Report for Q1 Ended Mar 31, 2024

Intuitive Surgical Inc. (ISRG) reported strong financial results for the first quarter of 2024, demonstrating robust growth across key operational and financial metrics. Total revenue increased by 11% year-over-year to $1.89 billion, driven by a significant 18% rise in instruments and accessories revenue and an 11% increase in service revenue. The company also saw substantial procedure growth, with da Vinci procedures up 16% and Ion procedures nearly doubling at a 90% increase. This growth is supported by an expanding installed base of da Vinci systems, up 14% year-over-year, and a 61% increase in Ion systems. Despite a slight 2% decrease in systems revenue, attributed to a higher proportion of systems placed under operating leases, the company's operational performance remains strong. Profitability also improved, with operating income increasing by 21% and gross profit margin holding steady at 65.9%. The company ended the quarter with a healthy cash position of $7.32 billion.

Apr 19, 2024 8-K

Intuitive Surgical 8-K Report, Financial Results (Apr 18, 2024)

Intuitive Surgical reported first-quarter 2024 revenue of $1.89 billion, up 11% from $1.70 billion a year earlier, driven by roughly 16% growth in da Vinci procedure volume and about 90% growth in Ion procedure volume. Instruments and accessories revenue rose 18% to $1.16 billion, the core recurring engine of the business. Systems revenue was roughly flat at $418 million, with 313 da Vinci placements versus 312 a year ago, and the installed base reached 8,887 systems, up 14%. Revenue was down sequentially from $1.93 billion in Q4 2023, and systems revenue fell from $480 million, though Q4 had different one-time items. Profitability improved meaningfully. GAAP income from operations rose to $469 million from $388 million, and non-GAAP operating income rose to $630 million from $535 million. GAAP diluted EPS was $1.51 versus $1.00, but that figure includes a $0.31 per-share benefit from excess tax benefits on share-based compensation. Non-GAAP diluted EPS was $1.50 versus $1.23, a more representative measure of operating performance. Cash, cash equivalents, and investments were $7.32 billion, down only $21 million in the quarter as capital expenditures offset operating cash generation. Strategically, management highlighted the measured launch of da Vinci 5 (FDA-cleared in March 2024 for most Xi indications, with 8 units placed), CE mark certification and early European placements of the da Vinci SP (8 units), and NMPA clearance in China for the Ion system. Placements under operating leases rose to 159 from 131, with usage-based leases at 94 versus 62, which supports recurring revenue but defers system revenue recognition. The filing itself is a furnished (not filed) 8-K attaching the earnings release.

Apr 18, 2024 8-K

Intuitive Surgical 8-K Report, Regulation FD Disclosure (Mar 14, 2024)

Intuitive Surgical (ISRG) announced on March 14, 2024 that the U.S. FDA granted 510(k) clearance for da Vinci 5, its fifth-generation multiport robotic surgical system. The filing is a Regulation FD disclosure (Item 7.01) furnishing a press release as Exhibit 99.1, so the information is not deemed "filed" under Section 18 of the Exchange Act. No financial results, guidance, or quantitative financial metrics are included in this 8-K, so investors should treat it primarily as a product and strategic milestone rather than a change to reported financials. The press release positions da Vinci 5 as a successor to da Vinci Xi, which has been used in more than 7 million procedures, and cites over 150 enhancements. Headline features include Force Feedback technology that measures forces on tissue (preclinical trials showed up to 43% less force exerted on tissue), more than 10,000 times the computing power of da Vinci Xi, integrated insufflation and electrosurgical capabilities, and a redesigned, more ergonomic surgeon console. The company frames these as tools for better patient outcomes, workflow efficiency, and lower total cost of care. Commercial rollout will be gradual. Da Vinci 5 will first be offered to a small number of U.S. customers who collaborated on development or have mature robotic programs, with Intuitive gathering additional clinical data before a broader U.S. and global launch. Management will discuss launch plans on a teleconference on March 18, 2024. Investors should watch the timing and pace of the broader launch, adoption by hospitals, pricing, and regulatory and competitive developments, since the 8-K provides none of these details.

Mar 14, 2024 10-K

Intuitive Surgical Annual Report, Year Ended Dec 31, 2023

Intuitive Surgical Inc. (ISRG) demonstrated robust financial performance in its 2023 fiscal year, reporting a 14% increase in total revenue to $7.1 billion. This growth was primarily driven by a strong 22% increase in instruments and accessories revenue, reflecting higher da Vinci procedure volumes, which rose 22% to approximately 2.3 million procedures. The company also saw a significant 129% surge in Ion procedures. Despite flat systems revenue, the installed base of da Vinci systems grew by 14% to 8,606 units, indicating continued market penetration and utilization. The company's strategic focus on expanding its minimally invasive care ecosystem, including its Ion endoluminal system, and its commitment to innovation and customer training are key drivers of its success. While facing macroeconomic headwinds such as inflation and higher interest rates, which have impacted customer capital spending, ISRG has managed its operations effectively, maintaining a solid cash position and continuing to invest in research and development to drive future growth. The company's extensive risk factor disclosures highlight the competitive landscape, regulatory environment, and supply chain challenges as areas of ongoing attention.

Jan 31, 2024 8-K

Intuitive Surgical 8-K Report, Financial Results (Jan 23, 2024)

Intuitive Surgical reported strong fourth-quarter 2023 results, with revenue of $1.93 billion, up 17% from $1.66 billion a year earlier. Growth was led by worldwide da Vinci procedure volume, which rose about 21%, and by a higher installed base. Instruments and accessories revenue grew 22% to $1.14 billion, supported by procedure growth and higher pricing, partly offset by customer buying patterns. Systems revenue rose to $480 million from $451 million on 415 placements, compared with 369 a year earlier. Service revenue increased to $304 million from $263 million. The da Vinci installed base reached 8,606 systems, up 14%. Full-year 2023 revenue was $7.12 billion, up from $6.22 billion in 2022. Profitability is harder to read than the top line. GAAP net income attributable to Intuitive was $606 million, or $1.69 per diluted share, versus $325 million, or $0.91, a year earlier. That figure includes roughly $0.45 per share of one-time Swiss tax benefits and a $0.09 per share net charge from a $40 million contribution to the Intuitive Foundation. Excluding these and other non-GAAP items, net income was $574 million, or $1.60 per diluted share, up about 30% from $1.23. Non-GAAP operating income rose to $621 million from $530 million. Operating expenses rose sharply, with SG&A reaching $567 million, which includes the Foundation contribution. Cash, cash equivalents, and investments ended the quarter at $7.34 billion, down $177 million on capital expenditures. The release contains no forward guidance, and the company said the quarter had no significant COVID-19 disruption. In January 2024 it also received CE mark certification for the da Vinci SP system, with a measured European rollout planned for 2024.

Jan 23, 2024 8-K

Intuitive Surgical 8-K Report, Financial Results (Jan 9, 2024)

Intuitive Surgical (ISRG) furnished an 8-K on January 9, 2024 disclosing unaudited preliminary fourth quarter and full year 2023 results ahead of its J.P. Morgan Healthcare Conference presentation. Preliminary full-year 2023 revenue was approximately $7.12 billion, up 14% from $6.22 billion in 2022, while Q4 2023 revenue was approximately $1.93 billion, up 17%. Growth was led by instruments and accessories (I&A), which rose 22% to about $4.28 billion for the year, driven by da Vinci procedure volume growth and higher I&A pricing, partially offset by customer buying patterns. Systems revenue was flat for the full year at about $1.68 billion, though Q4 systems revenue rose 6%. Services revenue grew 14% for the year to about $1.17 billion, and recurring revenue made up roughly 83% of total 2023 revenue. Procedure volume was the central story. Worldwide da Vinci procedures grew approximately 22% in 2023 to about 2.29 million, with U.S. general surgery procedures up 25% and outside-the-U.S. procedures up 27%, mainly from cancer procedures. Placements reached 1,370 systems for the year (up 8%) and 415 in Q4 (up 12%), with Asia and usage-based operating leases showing notable gains. Management guided to 13% to 16% worldwide procedure growth in 2024. Investors should note that all figures are preliminary and unaudited, since the company had not yet filed its 2023 Form 10-K, and results remain subject to final closing procedures and audit adjustments. The company also said it would report full Q4 2023 results on January 23, 2024. The 2022 Q4 comparison was depressed by COVID-19 in China, which flatters year-over-year growth rates somewhat.

Jan 9, 2024 8-K

Intuitive Surgical 8-K Report, Executive Changes (Oct 31, 2023)

Intuitive Surgical (ISRG) filed an 8-K on October 31, 2023 reporting a board change rather than a financial or operational event. The Board appointed Sreelakshmi Kolli as a director effective October 27, 2023, and increased the Board from 11 to 12 authorized members. Ms. Kolli is executive vice president and chief digital officer at Align Technology and sits on the Zimmer Biomet board. The filing contains no earnings, guidance, or material financial results. Compensation for Ms. Kolli follows the standard non-employee director program: a prorated $70,000 annual cash retainer, plus initial equity grants on November 10, 2023 of stock options and RSUs each targeted at $70,000. Share counts are set from the 60 trading-day average closing price, and the awards vest on the earlier of the first anniversary of grant or the next annual meeting. She also signed the company's standard indemnification agreement and has no related-party transactions requiring disclosure under Item 404(a). For investors, the appointment is a governance and succession update with limited direct financial impact. The company framed it as part of ongoing board balancing and succession planning, and the CEO cited her expertise in digital capabilities and customer experience as relevant to the company's strategy in minimally invasive care.

Oct 31, 2023 10-Q

Intuitive Surgical Quarterly Report for Q3 Ended Sep 30, 2023

Intuitive Surgical Inc. (ISRG) reported robust financial performance for the nine months ended September 30, 2023, with total revenue reaching $5.20 billion, a 14% increase year-over-year. This growth was driven by strong performance in instruments and accessories (up 22%) and service revenue (up 13%), indicating increased utilization of their da Vinci surgical systems. While system revenue saw a slight decrease of 2%, this was offset by a higher proportion of placements under operating leases, which generate recurring revenue over time. The company demonstrated solid profitability with an operating income of $1.32 billion for the nine-month period, up 9% year-over-year. Net income attributable to Intuitive Surgical, Inc. increased by 19% to $1.19 billion. The company maintained a strong liquidity position, with cash, cash equivalents, and investments totaling $7.52 billion as of September 30, 2023. ISRG also continued its commitment to shareholder returns, repurchasing $350 million of its common stock during the nine-month period, while maintaining a significant remaining authorization for future repurchases.

Oct 20, 2023 8-K

Intuitive Surgical 8-K Report, Financial Results (Oct 19, 2023)

Intuitive Surgical (ISRG) reported third-quarter 2023 results that show strong top-line momentum and solid profitability. Revenue rose 12% year over year to $1.74 billion, driven by worldwide da Vinci procedure growth of roughly 19%, which lifted instruments and accessories revenue 23% to $1.07 billion. GAAP net income attributable to Intuitive was $416 million ($1.16 per diluted share), up from $324 million ($0.90) a year earlier, and non-GAAP EPS was $1.46 versus $1.19. The installed base grew 13% to 8,285 systems, and the company placed 312 systems, up from 305. The main watch items are systems revenue, which declined to $379 million from $426 million despite higher placements, reflecting a higher mix of usage-based operating leases (93 of 163 leased placements, versus 54 of 113 a year earlier). Gross margin was roughly flat sequentially, with product costs and inventory rising faster than revenue (inventory up to $1.15 billion from $893 million at year-end 2022). Operating expenses grew, with R&D up 15% year over year. Cash and investments reached $7.52 billion, and equity increased to $12.6 billion, leaving the balance sheet strong. The filing itself is a routine earnings disclosure under Item 2.02 and Exhibit 99.1; the press release is furnished, not filed. Investors will likely focus on procedure growth sustainability, the shift toward usage-based leasing, and the ramp of the Ion and SP platforms that management highlighted.

Oct 19, 2023 10-Q

Intuitive Surgical Quarterly Report for Q2 Ended Jun 30, 2023

Intuitive Surgical, Inc. (ISRG) reported robust performance in its second quarter and first half of 2023, demonstrating continued growth in revenue and procedures. Total revenue increased by 15% year-over-year for the quarter, reaching $1.76 billion, driven by strong performance in instruments and accessories, services, and systems. This growth was fueled by a significant 22% increase in da Vinci procedures globally, alongside a substantial 145% rise in Ion procedures. The company continues to expand its installed base, with da Vinci surgical systems increasing by 13% year-over-year to 8,042, and the Ion system seeing over a 100% increase in its installed base. Profitability remains strong, with operating income up 16% year-over-year for the quarter. Despite ongoing macroeconomic challenges such as inflation and supply chain pressures, ISRG has managed to mitigate these impacts, reporting that supply chain disruptions have not materially affected results to date. The company maintains a strong liquidity position with $7.13 billion in cash, cash equivalents, and investments as of June 30, 2023.

Jul 24, 2023 8-K

Intuitive Surgical 8-K Report, Financial Results (Jul 20, 2023)

Intuitive Surgical (ISRG) reported Q2 2023 results on July 20, 2023, showing strong top-line and profit growth. Total revenue rose about 15% year over year to $1.76 billion (up 16.7% in constant currency), driven by worldwide da Vinci procedure volume growth of approximately 22%. Instruments and accessories revenue, the most important recurring driver, grew 20% to $1.08 billion, while systems revenue increased modestly to $393 million on 331 placements, up from 279 a year earlier. The installed base reached 8,042 systems, up 13%. Profitability improved meaningfully. GAAP operating income rose to $463 million from $398 million, and GAAP diluted EPS was $1.18 versus $0.85. Non-GAAP diluted EPS was $1.42 versus $1.14. Gross margin was roughly 66.7% on a GAAP basis. Share-based compensation of $148 million remains a significant recurring cost, and GAAP net income benefited from $42 million in excess tax benefits (about $0.12 per share). The company ended the quarter with $7.13 billion in cash, cash equivalents, and investments, up $553 million in the quarter. The filing itself is a routine Item 2.02 disclosure furnishing the earnings press release as Exhibit 99.1. The information is furnished rather than filed and is not subject to Section 18 liability. Management said the quarter did not reflect significant COVID-19 disruptions, though the company cautioned that the pandemic could still affect procedure volumes, and it flagged macroeconomic, supply chain, and regulatory risks.

Jul 20, 2023 8-K

Intuitive Surgical 8-K Report, Executive Changes (May 16, 2023)

Intuitive Surgical (ISRG) announced on May 16, 2023 an executive leadership reshuffle. David J. Rosa, a 27-year company veteran most recently serving as EVP and Chief Strategy and Growth Officer, was promoted to President, effective immediately. He will oversee the core business, including product, digital, quality, regulatory, supply chain, manufacturing, and commercial teams. Gary Guthart relinquishes the President title but remains CEO and a board member, focusing on market presence, overall strategy, governance, culture, and early-stage business and product initiatives. Rosa and Bob DeSantis, who moves into a newly created role of EVP and Chief Strategy and Corporate Operations Officer, will both report directly to Guthart. For investors, the filing signals an organizational restructuring rather than a change in financial outlook. The filing contains no earnings, revenue, or guidance information, and the disclosure is limited to governance and compensation. The move consolidates operational and commercial responsibilities under a single leader, which the company frames as preparing it to pursue large-scale collaborations with hospitals and healthcare systems. Because the reporting lines remain unchanged and the CEO stays in place, the immediate operational risk appears modest, though the depth of management succession is now more concentrated in Rosa. Rosa's compensation package was adjusted to reflect his expanded role. His base salary rises from $652,468 to $700,000, his fiscal 2023 bonus target increases from 100% to 120% of base salary, and he receives equity grants worth roughly $5.0 million in total, split among stock options, RSUs, and PSUs. The filing also notes that Rosa has no related-party transactions requiring disclosure under Item 404(a). The announcement was furnished under Regulation FD and is not deemed filed for Exchange Act liability purposes.

May 16, 2023 8-K

Intuitive Surgical 8-K Report, Shareholder Vote Results (May 2, 2023)

Intuitive Surgical, Inc. (ISRG) held its Annual Meeting of stockholders, where shareholders voted on five proposals as described in the Proxy Statement filed with the Securities and Exchange Commission on March 10, 2023. All eleven director nominees were elected to one-year terms expiring at the 2024 Annual Meeting. Each nominee received more votes For than Against, with Craig H. Barratt, Ph.D. receiving 272,570,649 For and 9,717,456 Against, and Alan J. Levy, Ph.D. receiving 264,252,132 For and 18,614,155 Against. Stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers, with 256,335,720 votes For and 23,958,341 Against. In a separate advisory vote on the frequency of say-on-pay votes, 280,214,412 shares voted for one year, and the annual frequency was approved. As a result, the Company will hold an advisory, non-binding executive compensation vote annually until the next frequency vote, which will occur no later than the 2029 Annual Meeting of Shareholders. Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 306,654,434 For and 1,157,337 Against. A stockholder proposal regarding pay equity disclosure was rejected, receiving 98,764,665 For and 180,992,684 Against.

May 2, 2023 10-Q

Intuitive Surgical Quarterly Report for Q1 Ended Mar 31, 2023

Intuitive Surgical, Inc. (ISRG) reported its first-quarter 2023 financial results, showcasing robust growth driven by increased da Vinci procedure volumes and strong performance in instruments and accessories. Total revenue grew 14% year-over-year to $1.7 billion, with instruments and accessories revenue up 22% to $986 million, largely fueled by a 26% increase in da Vinci procedures globally. While systems revenue remained flat year-over-year at $427 million, this was driven by higher leasing revenue, offsetting a greater proportion of systems placed under operating leases. The company maintained a strong installed base, with da Vinci systems growing 12% to 7,779 and Ion systems growing 131% to 376. Despite revenue growth, operating income saw a slight decrease of 5% to $388 million, primarily due to increased operating expenses, including higher R&D and SG&A costs related to investments in future growth and share-based compensation. The company's gross profit margin also compressed slightly to 65.6% from 67.9% in the prior year, impacted by higher component and labor costs. Intuitive Surgical ended the quarter with a healthy cash position of $6.58 billion, but significant share repurchases and capital expenditures are noted. Key risks and considerations include ongoing macroeconomic challenges such as inflation and rising interest rates, which may impact hospital capital spending, as well as supply chain constraints that continue to pose a challenge. The company is actively managing these risks while investing in innovation and expanding its global reach.

Apr 20, 2023 8-K

Intuitive Surgical 8-K Report, Financial Results (Apr 18, 2023)

Intuitive Surgical (ISRG) reported first-quarter 2023 results that showed strong top-line momentum driven by da Vinci procedure growth. Total revenue rose 14% year over year to $1.70 billion (17% on a constant-currency basis, with foreign exchange a roughly 3-point headwind). Worldwide da Vinci procedures grew approximately 26%, offsetting COVID-19 disruptions in China during January. Instruments and accessories revenue rose 22% to $986 million, the clearest signal of recurring procedure-driven demand, while systems revenue was flat at $427 million on 312 placements (vs. 311 a year earlier). The installed base reached 7,779 systems, up 12%. Services revenue also grew, to $283 million. Profitability was mixed on a GAAP basis. Income from operations fell to $388 million from $408 million, largely because share-based compensation rose to $141 million from $121 million and SG&A grew to $480.5 million. GAAP diluted EPS was $1.00, flat year over year. Non-GAAP diluted EPS rose to $1.23 from $1.13, and non-GAAP operating income was roughly flat at $535 million, so margin pressure from operating expense growth remains the key watch item. Excess tax benefits from stock compensation, which contributed $0.06 to GAAP EPS versus $0.14 a year earlier, also weighed on GAAP results. The balance sheet remains strong, with $6.58 billion in cash, equivalents, and investments after $350 million of share repurchases and capital expenditures, and stockholders' equity of $11.3 billion. The company also obtained European certification for its Ion endoluminal system in March 2023, with an initial UK focus. The filing contains no formal guidance, and investors should note that the 8-K was furnished under Item 2.02 and is not deemed filed under the Exchange Act.

Apr 18, 2023 10-K

Intuitive Surgical Annual Report, Year Ended Dec 31, 2022

Intuitive Surgical, Inc. (ISRG) filed its 2022 10-K report, detailing its continued growth in a dynamic global healthcare landscape. The company saw an 18% increase in da Vinci procedures, reaching approximately 1.875 million, alongside a substantial 218% rise in Ion system procedures to 23,500. This procedural growth drove a 13% increase in instruments and accessories revenue, highlighting the recurring revenue model's strength. However, systems revenue saw a slight 1% decrease, attributed to macroeconomic pressures, particularly in the U.S., which impacted hospital capital spending, and a 6% decline in da Vinci system placements. Despite these system placement challenges, the overall installed base of da Vinci systems grew by 12% to 7,544 units, indicating ongoing market penetration and adoption. The company's financial performance in 2022 showed total revenue growth of 9% to $6.2 billion, though operating income decreased by 13% to $1.58 billion, impacted by increased investments in R&D and SG&A expenses, including higher headcount and infrastructure costs. The gross profit margin also saw a slight decrease to 67.4% from 69.3% in the prior year, influenced by rising freight and material costs and unfavorable foreign currency impacts. Looking ahead, Intuitive Surgical faces ongoing risks related to macroeconomic conditions, supply chain constraints, and potential regulatory changes. The company is actively managing these challenges by focusing on innovation, expanding its product portfolio, and investing in its global infrastructure to support long-term growth and its mission of advancing minimally invasive care.

Feb 10, 2023 8-K

Intuitive Surgical 8-K Report, Financial Results (Jan 24, 2023)

Intuitive Surgical (ISRG) reported Q4 2022 results that showed strong underlying demand but a mixed profit picture. Worldwide da Vinci procedures grew approximately 18% year over year, and the installed base reached 7,544 systems, up 12%. Revenue rose 7% to $1.66 billion (10% on a constant-currency basis), with instruments and accessories up 12% to $941 million. Systems revenue fell 4% to $451 million on 369 placements, down from 385. China COVID-19 resurgence weighed on procedure volumes in the quarter. Profitability was weaker than the top line. GAAP income from operations fell to $373 million from $450 million, mainly because R&D rose to $244 million from $183 million and SG&A rose to $494 million from $427 million. GAAP diluted EPS was $0.91 versus $1.04, and non-GAAP diluted EPS was $1.23 versus $1.29. Share-based compensation was $129 million, and a $21 million litigation charge was recorded. Management repurchased $1 billion of stock in the quarter, which reduced cash, cash equivalents, and investments to $6.74 billion from $8.62 billion a year earlier. For investors, the key takeaways are the continued procedure growth and expanding installed base, offset by softer system placements, higher operating expenses, and margin pressure. The filing itself is a furnished earnings release under Item 2.02, so the information is not deemed filed under Section 18 of the Exchange Act.

Jan 24, 2023